In 2026, 25 healthcare & pharma companies have cut a combined 27,790 jobs, averaging 18.7% of workforce per company.
Healthcare and pharma layoffs in 2026 are driven by clinical trial failures, regulatory setbacks, and cost restructuring. Biotech companies like Theravance and Gossamer Bio face existential cuts after late-stage trial failures, while larger pharma firms like Merck and Viatris are optimizing for efficiency.
| Company | People Cut | % of Workforce | Date | Category |
|---|---|---|---|---|
| Takeda | 4,500 | 9.2% | COST CUT | |
| Novo Nordisk | 4,000 | 6.0% | RESTRUCTURE | |
| Viatris | 3,200 | 8.6% | COST CUT | |
| BioNTech | 1,860 | 22.0% | WEAK DEMAND | |
| Conifer Health (Tenet) | 1,037 | 1.0% | WEAK DEMAND | |
| CorroHealth | 800 | 4.7% | RESTRUCTURE | |
| Evotec | 800 | 16.0% | RESTRUCTURE | |
| Crothall / Morrison Healthcare | 795 | 8.0% | RESTRUCTURE | |
| Wellstar Health System | 761 | 2.2% | RESTRUCTURE | |
| 24Hr HomeCare | 738 | 5.7% | RESTRUCTURE | |
| GSK | 650 | 1.0% | WEAK DEMAND | |
| Trinity Health | 557 | 0.4% | RESTRUCTURE | |
| Crothall / Morrison Healthcare | 545 | 5.5% | RESTRUCTURE | |
| Owens & Minor | 419 | 3.0% | RESTRUCTURE | |
| Novartis | 322 | 0.4% | WEAK DEMAND | |
| Texas Family Initiative | 307 | 19.2% | WEAK DEMAND | |
| Bristol Myers Squibb | 265 | 0.8% | COST CUT | |
| Sharp HealthCare | 260 | 1.2% | RESTRUCTURE | |
| Teva | 250 | 0.7% | RESTRUCTURE | |
| Bristol Myers Squibb | 247 | 0.7% | COST CUT | |
| Horizon BCBS NJ | 242 | 5.0% | COST CUT | |
| Alameda Health System | 240 | 4.0% | COST CUT | |
| Sanofi | 229 | 0.3% | MERGER | |
| L.A. Care Health Plan | 225 | 3.0% | COST CUT | |
| Elevance Health | 216 | 0.2% | RESTRUCTURE | |
| Health First | 214 | 2.1% | RESTRUCTURE | |
| Bristol Myers Squibb | 206 | 0.6% | COST CUT | |
| Theravance Biopharma | 200 | 50.0% | RESTRUCTURE | |
| University of Vermont Health Network | 199 | 1.3% | COST CUT | |
| Gilead Sciences | 192 | 91.9% | MERGER | |
| Replimune | 161 | 59.6% | COST CUT | |
| Molina Healthcare | 156 | 0.9% | RESTRUCTURE | |
| PeaceHealth | 150 | 0.9% | RESTRUCTURE | |
| Kaiser Permanente | 147 | 0.1% | RESTRUCTURE | |
| Merck | 147 | 0.2% | WEAK DEMAND | |
| MultiCare Health System | 138 | 0.5% | COST CUT | |
| Cigna Evernorth | 134 | 0.2% | RESTRUCTURE | |
| Novartis | 130 | 0.2% | RESTRUCTURE | |
| MedImpact Healthcare | 125 | 6.2% | MERGER | |
| Dartmouth Health | 124 | 0.8% | COST CUT | |
| BioMarin Pharmaceutical | 117 | 3.6% | RESTRUCTURE | |
| TScan Therapeutics | 104 | 75.4% | RESTRUCTURE | |
| GoHealth | 103 | 12.1% | RESTRUCTURE | |
| Genentech | 103 | 0.8% | RESTRUCTURE | |
| UCare | 102 | 7.0% | RESTRUCTURE | |
| Cellares | 100 | 31.4% | WEAK DEMAND | |
| ArsenalBio | 99 | 78.0% | RESTRUCTURE | |
| Autolus Therapeutics | 98 | 13.0% | RESTRUCTURE | |
| Stanford Health Care | 95 | 0.6% | RESTRUCTURE | |
| Emergent BioSolutions | 93 | 7.9% | RESTRUCTURE | |
| Tessera Therapeutics | 90 | 36.0% | RESTRUCTURE | |
| Johnson & Johnson | 87 | 0.1% | RESTRUCTURE | |
| Bicycle Therapeutics | 86 | 29.9% | COST CUT | |
| MaineHealth | 83 | 0.4% | RESTRUCTURE | |
| Thermo Fisher | 80 | 0.1% | RESTRUCTURE | |
| John Muir Health | 78 | 1.3% | RESTRUCTURE | |
| Gossamer Bio | 77 | 48.1% | RESTRUCTURE | |
| Cellares | 68 | 21.4% | WEAK DEMAND | |
| Blue Shield of California | 60 | 0.8% | RESTRUCTURE | |
| Johnson & Johnson | 56 | 0.0% | RESTRUCTURE | |
| Merck | 54 | 0.1% | COST CUT | |
| Disc Medicine | 30 | 20.0% | RESTRUCTURE | |
| Vertex Pharma | 20 | 0.2% | RESTRUCTURE | |
| Alltrna | 19 | 34.5% | RESTRUCTURE |